Intravenous thrombolytic therapy in myocardial infarction (review)

About the authors

I I Staroverov

References

  1. Fletcher A. P., Alkjaersig N., Smyrniotis F. E. et al. The treatment of patients suffering from early MI with massive and prolonged SK therapy. Trans. Assoc. Am. Phys. 1958; 71: 287.
  2. Чазов Е. И., Андреенко Г. В. Экспериментальное обоснование терапии лизируюшими препаратами. В кн.: Совещание по применению антикоагулянтов. Л.; 1961.
  3. Gruppo Italiano per lo Studio della Streptochinasi nelP Infarcts Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
  4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Ibid. 1988; 2: 349-360.
  5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med 1993; 329: 673-682.
  6. Hosai В., Begar S., Wallentin L. et al. A prospective survey of the characteristics, treatment and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur. Heart J. 2002; 15 (1): 1190- 2001.
  7. Widimsky P., Groch L., Zelizko M. et al. Multicenter randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The Prague Study. Ibid. 2000; 21: 823-831.
  8. Andersen H. R. On behalf of the DANAMI-2 trial investigators. Final results of the DANAMI-2 trial. Presented Late breaking clinical trials session at the Annual meeting of the American College of Cardiology, March 2002.
  9. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N. Engl. J. Med. 1986; 314: 1465-1471.
  10. EMERAS (Estudio Multicentrico Estptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.
  11. The TIMI Study Group Thrombolysis in Myocardial Infarction (TIMI). Trial phase I findings. N. Engl. J. Med. 1985; 312: 932-936.
  12. Neuhaus K. L., Feuerer W., Jeep-Tebble S. et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. 1989; 14: 1566-1569.
  13. Cannon С. P., McCabe С. Н., Diver D. J. et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Ibid. 1994; 24: 1602-1610.
  14. Intravenous NPA for the treatment of infracting myocardial early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart. J. 2000: 21:2005-2013.
  15. International Joint Efficacy Comparison of Thrombolytics. Randomized, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. (Published erratum appears in Lancet 1995; 346 (8980): 980). Lancet 1995; 346: 329-336.
  16. The Global Use of Strategies to Open Occluded Coronary Arteries (Gusto III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N. Engl. Med. 1997; 337: 1118-1123.
  17. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Circulation 1998: 98: 2805-2814.
  18. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the safety and efficacy of a new thrombolytic investigators. Lancet 1999; 354: 716-722.

Statistics

Views

Abstract - 96

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2003 Staroverov I.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies